Kindred Biosciences (NASDAQ:KIN) is set to announce its earnings results after the market closes on Thursday, August 1st. Analysts expect the company to announce earnings of ($0.36) per share for the quarter.
Kindred Biosciences (NASDAQ:KIN) last issued its quarterly earnings data on Thursday, May 9th. The biopharmaceutical company reported ($0.42) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.41) by ($0.01). The company had revenue of $0.52 million for the quarter, compared to analysts’ expectations of $1.95 million. On average, analysts expect Kindred Biosciences to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.
Shares of NASDAQ:KIN opened at $7.00 on Wednesday. The company has a market capitalization of $262.11 million, a PE ratio of -4.38 and a beta of 0.45. Kindred Biosciences has a 1 year low of $5.96 and a 1 year high of $15.75. The stock has a fifty day simple moving average of $7.70. The company has a debt-to-equity ratio of 0.01, a current ratio of 9.10 and a quick ratio of 8.70.
A number of equities research analysts recently issued reports on KIN shares. Guggenheim reiterated a “buy” rating and issued a $95.00 price objective (up from $90.00) on shares of VF in a report on Thursday, May 23rd. Stifel Nicolaus set a $154.00 price objective on shares of argenx and gave the stock a “buy” rating in a report on Wednesday, May 22nd. Cantor Fitzgerald set a $135.00 price objective on shares of Zimmer Biomet and gave the stock a “buy” rating in a report on Friday, April 26th. ValuEngine cut shares of Zynerba Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Wednesday, July 17th. Finally, Zacks Investment Research upgraded shares of Zurich Insurance Group from a “sell” rating to a “hold” rating in a report on Saturday, May 18th. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and seven have given a buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus price target of $14.28.
Kindred Biosciences Company Profile
Kindred Biosciences, Inc, a commercial-stage biopharmaceutical company, focusing on developing therapies for pets. Its product pipeline consists of small molecules and biologics for a range of indications in dogs, cats, and horses. The company offers Mirataz, a mirtazapine transdermal ointment for the management of weight loss in cats.
Recommended Story: Percentage Decliners
Receive News & Ratings for Kindred Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kindred Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.